Fernandez-NebroAMarenco de la FuenteJLCarrenoL. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study. Lupus2012; 21: 1063–1076.
2.
El-HallakMBinstadtBALeichtnerAM. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases. J Pediatr2007; 150: 376–382.
3.
PodolskayaAStademannMPilkingtonCMarksSDKullusK. B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus. Arch Dis Child2008; 93: 401–306.
4.
TrachanaMKoutsonikoliAFarmakiEPrintzaNTzimouliVPapachristouF. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: A single-center experience of Northern Greece. Rheumatol Int2013; 33: 809–813.
5.
SuzukiKTanakaHTsugawaKItoE. Effective treatment with cyclosporine A of a child with systemic lupus erythematosus resistant to cyclophosphamide pulse therapy. Tohoku J Exp Med2006; 208: 355–359.
6.
KameiKItoSNozuK. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome. Pediatr Nephrol2009; 24: 1321–1328.
